283 related articles for article (PubMed ID: 28747172)
1. Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants.
Sánchez Ramírez J; Morera Díaz Y; Bequet-Romero M; Hernández-Bernal F; Selman-Housein Bernal KH; de la Torre Santos A; Santiesteban Álvarez ER; Martín Bauta Y; Bermúdez Badell CH; de la Torre Pupo J; Gavilondo JV; ; Ayala Avila M
BMC Immunol; 2017 Jul; 18(1):39. PubMed ID: 28747172
[TBL] [Abstract][Full Text] [Related]
2. Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program.
Sánchez Ramírez J; Morera Díaz Y; Bequet-Romero M; Hernández-Bernal F; Martín Bauta Y; Selman-Housein Bernal KH; de la Torre Santos AV; Pérez de la Iglesia M; Trimiño Lorenzo L; ; Ayala Avila M
BMC Immunol; 2020 Mar; 21(1):12. PubMed ID: 32171254
[TBL] [Abstract][Full Text] [Related]
3. Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. results of the CENTAURO antigen dose escalation phase I clinical trial.
Gavilondo JV; Hernández-Bernal F; Ayala-Ávila M; de la Torre AV; de la Torre J; Morera-Díaz Y; Bequet-Romero M; Sánchez J; Valenzuela CM; Martín Y; Selman-Housein KH; Garabito A; Lazo OC;
Vaccine; 2014 Apr; 32(19):2241-50. PubMed ID: 24530151
[TBL] [Abstract][Full Text] [Related]
4. Specific humoral and cellular immune responses in cancer patients undergoing chronic immunization with a VEGF-based therapeutic vaccine.
Morera Y; Sánchez J; Bequet-Romero M; Selman-Housein KH; de la Torre A; Hernández-Bernal F; Martín Y; Garabito A; Piñero J; Bermúdez C; de la Torre J; Ayala M; Gavilondo JV
Vaccine; 2017 Jun; 35(28):3582-3590. PubMed ID: 28536029
[TBL] [Abstract][Full Text] [Related]
5. Experimental studies of a vaccine formulation of recombinant human VEGF antigen with aluminum phosphate.
Pérez Sánchez L; Morera Díaz Y; Bequet-Romero M; Ramses Hernández G; Rodríguez Y; Castro Velazco J; Puente Pérez P; Ayala Avila M; Gavilondo JV
Hum Vaccin Immunother; 2015; 11(8):2030-7. PubMed ID: 25891359
[TBL] [Abstract][Full Text] [Related]
6. Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates.
Morera Y; Bequet-Romero M; Ayala M; Pérez PP; Castro J; Sánchez J; Alba JS; Ancízar J; Cosme K; Gavilondo JV
Vaccine; 2012 Jan; 30(2):368-77. PubMed ID: 22075086
[TBL] [Abstract][Full Text] [Related]
7. CIGB-247: a VEGF-based therapeutic vaccine that reduces experimental and spontaneous lung metastasis of C57Bl/6 and BALB/c mouse tumors.
Bequet-Romero M; Morera Y; Ayala-Ávila M; Ancizar J; Soria Y; Blanco A; Suárez-Alba J; Gavilondo JV
Vaccine; 2012 Feb; 30(10):1790-9. PubMed ID: 22240345
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates.
Morera Y; Bequet-Romero M; Ayala M; Velazco JC; Pérez PP; Alba JS; Ancizar J; Rodríguez M; Cosme K; Gavilondo JV
Vaccine; 2010 Apr; 28(19):3453-61. PubMed ID: 20197134
[TBL] [Abstract][Full Text] [Related]
9. Does VEGF-targeted active immunotherapy induce complete abrogation of platelet VEGF levels?
Sánchez Ramírez J; Bequet-Romero M; Morera Díaz Y; Hernández-Bernal F; Ayala Avila M
BMC Res Notes; 2019 Jun; 12(1):323. PubMed ID: 31182141
[TBL] [Abstract][Full Text] [Related]
10. Potential mechanisms involved on how systemic IgG antibodies specific to vascular endothelial growth factor (VEGF) and induced by active immunotherapy decrease platelet derived free-VEGF.
Sánchez Ramírez J; Morera Díaz Y; Bequet-Romero M; Ayala Ávila M
Platelets; 2022 Oct; 33(7):964-968. PubMed ID: 35373709
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants.
Morera Y; Bequet-Romero M; Ayala M; Lamdán H; Agger EM; Andersen P; Gavilondo JV
Angiogenesis; 2008; 11(4):381-93. PubMed ID: 19034678
[TBL] [Abstract][Full Text] [Related]
12. Specific active immunotherapy with the HEBERSaVax VEGF-based cancer vaccine: From bench to bedside.
Morera-Díaz Y; Gavilondo JV; Bequet-Romero M; Sánchez Ramírez J; Hernández-Bernal F; Selman-Housein KH; Perez L; Ayala-Ávila M
Semin Oncol; 2018 Jan; 45(1-2):68-74. PubMed ID: 30318086
[TBL] [Abstract][Full Text] [Related]
13. Indirect and competitive enzyme-linked immunosorbent assays for monitoring the humoral response against human VEGF.
Sánchez Ramírez J; Morera Díaz Y; Musacchio Lasa A; Bequet-Romero M; Muñoz Pozo Y; Pérez Sánchez L; Hernández-Bernal F; Mendoza Fuentes O; Selman-Housein KH; Gavilondo Cowley JV; Ayala Avila M
J Immunoassay Immunochem; 2016; 37(6):636-58. PubMed ID: 27143151
[TBL] [Abstract][Full Text] [Related]
14. HER1-based vaccine: Simultaneous activation of humoral and cellular immune response.
Bergado Báez G; Hernández Fernández DR; Mazorra Herrera Z; Sánchez Ramírez B
Semin Oncol; 2018 Jan; 45(1-2):75-83. PubMed ID: 30318087
[TBL] [Abstract][Full Text] [Related]
15. First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1.
Mahipal A; Ejadi S; Gnjatic S; Kim-Schulze S; Lu H; Ter Meulen JH; Kenney R; Odunsi K
Cancer Immunol Immunother; 2019 Jul; 68(7):1211-1222. PubMed ID: 31069460
[TBL] [Abstract][Full Text] [Related]
16. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.
Neuhaus V; Chichester JA; Ebensen T; Schwarz K; Hartman CE; Shoji Y; Guzmán CA; Yusibov V; Sewald K; Braun A
Vaccine; 2014 May; 32(26):3216-22. PubMed ID: 24731807
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
[TBL] [Abstract][Full Text] [Related]
18. An In vivo study: Adjuvant activity of poly-n-vinyl-2-pyrrolidone-co-acrylic acid on immune responses against Melanoma synthetic peptide.
Kızılbey K; Mansuroğlu B; Derman S; Mustafaeva Akdeste Z
Bioengineered; 2018 Jan; 9(1):134-143. PubMed ID: 28910565
[TBL] [Abstract][Full Text] [Related]
19. Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients.
Kawabata R; Wada H; Isobe M; Saika T; Sato S; Uenaka A; Miyata H; Yasuda T; Doki Y; Noguchi Y; Kumon H; Tsuji K; Iwatsuki K; Shiku H; Ritter G; Murphy R; Hoffman E; Old LJ; Monden M; Nakayama E
Int J Cancer; 2007 May; 120(10):2178-84. PubMed ID: 17278093
[TBL] [Abstract][Full Text] [Related]
20. Strengthened tumor antigen immune recognition by inclusion of a recombinant Eimeria antigen in therapeutic cancer vaccination.
Quiroga D; Aldhamen YA; Appledorn DM; Godbehere S; Amalfitano A
Cancer Immunol Immunother; 2015 Apr; 64(4):479-91. PubMed ID: 25655760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
